Comparative Pharmacokinetics and Safety of 3 Different Formulations of TNX-102 2.8 mg SL Tablets and Cyclobenzaprine 5 mg Oral Tablet in Healthy Adults

NCT01889173 | Completed Phase 1

• 1 other identifier: TNX-CY-F104
• Study Type: interventional
• Target: 24
• Locations: 1 country
• Sites: 1

Brief Summary

Very low dose (VLD) cyclobenzaprine at bedtime has shown promise as a treatment for fibromyalgia, but the chemistry of cyclobenzaprine requires new formulation technology for bedtime use. The present trial is designed to assess the safety and tolerability of 3 different formulations of TNX-102 2.8 mg SL Tablets (a new formulation of cyclobenzaprine designed to result in increased dosage precision and decreased potential for morning grogginess) and to compare the bio-availability of 3 different formulations of TNX-102 2.8 mg SL Tablets (TNX-102 with potassium phosphate, TNX-102-B with sodium phosphate, and TNX-102-C with trisodium citrate) to that of cyclobenzaprine (5 mg tablets).

Conditions

Healthy Adults

Outcome Measures

Primary Outcomes (2)

• Measured levels of cyclobenzaprine and norcyclobenzaprine in plasma and urine

  Blood samples will be taken per period: within 30 minutes pre-dose and 2, 3.5, 5, 10, 20, 30, and 45 minutes and 1, 2, 2.5, 3, 3.33, 3.67, 4, 4.33, 4.67, 5, 5.5, 6, 8, 12, 16, 24, 36, and 48 hours post-dose. A single urine sample will be collected within 30 minutes pre-dose (one sample), and urine will be pooled from 0-24 and 24-48 hours post-dose.

  26 time points per period for blood assessment ; 2 pooled analyses in urine.

• Safety and tolerability of the 3 formulations of TNX-102 SL Tablets at 2.8 mg

  Every adverse events occurring during the study period will be reported.

  Continuously until the end (day 3) of the study period + Telephone follow-up 7-13 days after dosing (total duration: about 1 month)

Study Arms (4)

TNX-102 SL Tablets at 2.8 mg

EXPERIMENTAL

1 x TNX-102 SL Tablets (with potassium phosphate) at 2.8 mg

Drug: TNX-102 SL Tablets at 2.8 mg

TNX-102-B SL Tablets at 2.8 mg

EXPERIMENTAL

1 x TNX-102-B SL Tablets (with sodium phosphate) at 2.8 mg

Drug: TNX-102-B SL Tablets at 2.8 mg

TNX-102-C SL Tablets at 2.8 mg

EXPERIMENTAL

1 x TNX-102-C SL Tablets (with trisodium citrate) at 2.8 mg

Drug: TNX-102-C SL Tablets at 2.8 mg

Cyclobenzaprine tablets

ACTIVE COMPARATOR

1 x 5 mg cyclobenzaprine oral tablet

Drug: Cyclobenzaprine tablets

Interventions

TNX-102 SL Tablets at 2.8 mg DRUG

1 x TNX-102 SL Tablet (with potassium phosphate) at 2.8 mg held under the tongue until dissolution, without swallowing or chewing it.

TNX-102 SL Tablets at 2.8 mg

TNX-102-B SL Tablets at 2.8 mg DRUG

1 x TNX-102-B SL Tablet (with sodium phosphate) at 2.8 mg held under the tongue until dissolution, without swallowing or chewing it.

TNX-102-B SL Tablets at 2.8 mg

TNX-102-C SL Tablets at 2.8 mg DRUG

1 x TNX-102-C SL Tablet (with trisodium citrate) at 2.8 mg held under the tongue until dissolution, without swallowing or chewing it.

TNX-102-C SL Tablets at 2.8 mg

Cyclobenzaprine tablets DRUG

1 x 5 mg cyclobenzaprine tablet, swallowed with 240 mL of room-temperature water

Cyclobenzaprine tablets

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Healthy adults
• Male or female
• years old
• Non-smoker
• BMI \> 18.5 and \< 30.0
• With medically acceptable form of contraception (female only)
• With signed informed consent

You may not qualify if:

• Any clinically significant abnormality including ECG abnormalities or vital sign abnormalities (systolic blood pressure \< 90 or \> 140 mmHg,
• Diastolic blood pressure lower \< 50 or \> 90 mmHg, or heart rate \< 50 or \> 100 BPM)
• Any abnormal laboratory test (including positivity for Hep B, Hep C, HIV, and
• Hemoglobin \< 128 g/L (males) or \< 115 g/L (females) and hematocrit \< 0.37 L/L (males) or \< 0.32 L/L (females))
• History of alcohol or drug abuse or dependence within 1 year and/or positive drug, cotinine, or alcohol tests
• Use of any drug (within 30 days), supplement, or food (within 14 days) known to induce or inhibit hepatic drug metabolism prior to study medication
• Positive pregnancy test, breastfeeding or lactating
• Use of medication other than hormonal contraceptives or topical products, including OTC, natural health products, MAO inhibitors
• Participation in an investigational study within 30 days prior to dosing
• Donation of plasma (within 7 days), or donation or loss of blood of 50-499 mL (within 30 days), or of \> 499 mL (within 56 days) prior to dosing.

Sponsors & Collaborators

• Tonix Pharmaceuticals, Inc.: lead

Study Sites (1)

PharmaNet, Inc.

Québec, Quebec, G1P 0A2, Canada

Location

MeSH Terms

Interventions

cyclobenzaprine

Study Officials

• Seth M. Lederman, MD

  Tonix Pharmaceuticals, Inc.

  STUDY CHAIR

• Jeffrey P. Kitrelle, MD

  Tonix Pharmaceuticals, Inc.

  STUDY DIRECTOR

• Denis Audet, MD

  PharmaNet

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 25, 2013
• First Posted: June 28, 2013
• Study Start: June 1, 2013
• Primary Completion: December 1, 2013
• Study Completion: March 1, 2014
• Last Updated: September 26, 2014

Record last verified: 2014-09

Locations

CA (1)